# Zavante Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zavante-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.zavante.com
- Total disclosed funding: $45M
- Latest round: Series A (Mar 30, 2016)
- Investors on record: 3

## About

Zavante Therapeutics develops innovative treatments for serious infections in hospitalized patients, focusing on advanced antibiotics for multi-drug resistant bacteria.Founded in 2015 and headquartered in San Diego, US, Zavante Therapeutics specializes in antibiotic development. The company was acquired by Nabriva Therapeutics GmbH in July 2018. Zavante has raised a total of USD 45.00 mn through 5 funding rounds, with the latest being a Venture Debt round of USD 10.00 mn led by Square 1 Bank.Zavante Therapeutics is focused on developing ZOLYD™ (fosfomycin for injection), an investigational antibiotic for treating multi-drug resistant infections in hospitalized patients. It primarily targets complicated urinary tract infections and has potential applications for complicated intra-abdominal infections and hospital-acquired bacterial pneumonia. The main customers are hospitals and healthcare providers in the US, addressing the urgent need for effective treatments against antimicrobial resistance.Zavante Therapeutics generates revenue through partnerships and direct sales of ZOLYD to hospitals and healthcare systems. The company has structured agreements with healthcare providers to ensure access to its antibiotic, facilitating treatment for patients with critical infections. This revenue model underpins ongoing research and development efforts in combating antibiotic resistance.Zavante Therapeutics aims to expand its product line and enhance market presence. The company is focused on potential new products to address additional indications and plans to broaden its reach within North America. The recent funding of USD 10.00 mn will support these initiatives, enhancing research capabilities and market development efforts.

## Funding rounds

- Series A, Mar 30, 2016, $45M — Frazier Healthcare Partners, Aisling Capital, Longitude Capital

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series A
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A